Opportunities and challenges of radiotherapy for treating cancer

D Schaue, WH McBride - Nature reviews Clinical oncology, 2015 - nature.com
The past 20 years have seen dramatic changes in the delivery of radiation therapy, but the
impact of radiobiology on the clinic has been far less substantial. A major consideration in …

Anticancer activities of histone deacetylase inhibitors

JE Bolden, MJ Peart, RW Johnstone - Nature reviews Drug discovery, 2006 - nature.com
Histone deacetylases (HDACs) are enzymes involved in the remodelling of chromatin, and
have a key role in the epigenetic regulation of gene expression. In addition, the activity of …

The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention

JP Alao - Molecular cancer, 2007 - Springer
Cyclin D1 is an important regulator of cell cycle progression and can function as a
transcriptionl co-regulator. The overexpression of cyclin D1 has been linked to the …

From signalling pathways to targeted therapies: unravelling glioblastoma's secrets and harnessing two decades of progress

B Dewdney, MR Jenkins, SA Best, S Freytag… - … and Targeted Therapy, 2023 - nature.com
Glioblastoma, a rare, and highly lethal form of brain cancer, poses significant challenges in
terms of therapeutic resistance, and poor survival rates for both adult and paediatric patients …

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

J Tan, S Cang, Y Ma, RL Petrillo, D Liu - Journal of hematology & oncology, 2010 - Springer
Histone deacetylases (HDACs) can regulate expression of tumor suppressor genes and
activities of transcriptional factors involved in both cancer initiation and progression through …

A phase 2 study of concurrent radiation therapy, temozolomide, and the histone deacetylase inhibitor valproic acid for patients with glioblastoma

AV Krauze, SD Myrehaug, MG Chang… - International Journal of …, 2015 - Elsevier
Purpose Valproic acid (VPA) is an antiepileptic agent with histone deacetylase inhibitor
(HDACi) activity shown to sensitize glioblastoma (GBM) cells to radiation in preclinical …

Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer

KT Thurn, S Thomas, A Moore, PN Munster - Future oncology, 2011 - Taylor & Francis
Histone deacetylases (HDACs) regulate the acetylation of a variety of histone and
nonhistone proteins, controlling the transcription and regulation of genes involved in cell …

Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy

TS Armstrong, R Grant, MR Gilbert, JW Lee… - Neuro …, 2016 - academic.oup.com
Seizures are a well-recognized symptom of primary brain tumors, and anticonvulsant use is
common. This paper provides an overview of epilepsy and the use of anticonvulsants in …

Epigenetics of cervical cancer. An overview and therapeutic perspectives

A Dueñas-González, M Lizano, M Candelaria, L Cetina… - Molecular cancer, 2005 - Springer
Cervical cancer remains one of the greatest killers of women worldwide. It is difficult to
foresee a dramatic increase in cure rate even with the most optimal combination of cytotoxic …

Medical management of brain tumors and the sequelae of treatment

D Schiff, EQ Lee, L Nayak, AD Norden… - Neuro …, 2015 - academic.oup.com
Patients with malignant brain tumors are prone to complications that negatively impact their
quality of life and sometimes their overall survival as well. Tumors may directly provoke …